Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Buy
- Symbol (MITO)
- Company Stealth BioTherapeutics Corp
- Price $0.32
- Changes Percentage (0%)
- Change -$0
- Day Low $0.32
- Day High $0.33
- Year High $0.97
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/17/2022
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.92
- Trailing P/E Ratio -0.34632034632035
- Forward P/E Ratio -0.34632034632035
- P/E Growth -0.34632034632035
- Net Income $-53,769,000
Income Statement
Quarterly
Annual
Latest News of MITO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Sumitomo Mitsui Financial Group, Inc. (SMFG): Hedge Funds Are Bullish On This Japanese Stock Now
A comprehensive analysis of Japan's economic landscape reveals a promising outlook for investors. Despite initial challenges in 2024, signs of recovery are evident. The shift in economic dynamics, cou...
By Yahoo! Finance | 1 week ago -
Premier Miton Group (LON:PMI) investors are sitting on a loss of 49% if they invested three years ago
Premier Miton Group plc (LON:PMI) stock has seen a 60% drop in the last three years compared to the market's 16% return. Despite a decline in EPS, the market remains optimistic with a P/E ratio of 50....
By Yahoo! Finance | 2 weeks ago -
Sumitomo Mitsui Financial Group, Inc. (SMFG): One of the Best Affordable Stocks Under $40 According to Short Sellers
The article discusses how short sellers profit from declining stock values and analyzes Sumitomo Mitsui Financial Group, Inc. as an affordable stock. It highlights the impact of short selling on inves...
By Yahoo! Finance | 4 weeks ago